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Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft 
dysfunction, leads to poor long-term survival after lung transplantation. Identifying pre-
dictors of BOS is essential to prevent the progression of dysfunction before irreversible 
damage occurs. By using a large set of 107 samples from lung recipients, we performed 
microarray gene expression profiling of whole blood to identify early biomarkers of BOS, 
including samples from 49 patients with stable function for at least 3 years, 32 samples 
collected at least 6 months before BOS diagnosis (prediction group), and 26 samples 
at or after BOS diagnosis (diagnosis group). An independent set from 25 lung recipients 
was used for validation by quantitative PCR (13 stables, 11 in the prediction group, and 
8 in the diagnosis group). We identified 50 transcripts differentially expressed between 
stable and BOS recipients. Three genes, namely POU class 2 associating factor 1 
(POU2AF1), T-cell leukemia/lymphoma protein 1A (TCL1A), and B  cell lymphocyte 
kinase, were validated as predictive biomarkers of BOS more than 6 months before 
diagnosis, with areas under the curve of 0.83, 0.77, and 0.78 respectively. These genes 
allow stratification based on BOS risk (log-rank test p < 0.01) and are not associated 
with time posttransplantation. This is the first published large-scale gene expression 
analysis of blood after lung transplantation. The three-gene blood signature could pro-
vide clinicians with new tools to improve follow-up and adapt treatment of patients likely 
to develop BOS.
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inTrODUcTiOn
Chronic lung allograft dysfunction is the main limitation of long-
term survival after lung transplantation. It manifests mainly by 
abnormal remodeling of the small airways, resulting in progres-
sive airflow obstruction called bronchiolitis obliterans syndrome 
(BOS) (1–3). The prevalence of BOS is around 35% at 5 years. Its 
late diagnosis, based on the irreversible decline of lung function, 
attests to irreversible and advanced degradation of the allograft. 
Prognosis is poor, with a 4-year median survival after disease 
diagnosis (4). Thus, there is an urgent need to identify the predic-
tors of BOS, which would allow proactive and targeted strategies 
to slow disease progression before irreversible degradation of the 
allograft occurs.
Bronchiolitis obliterans syndrome is likely to arise from 
repeated injuries from both alloimmune and non-alloimmune 
mechanisms, generating fibrosis and airway obstruction (5). 
Tracking these inflammation and fibrotic processes has been 
used to identify early signs of the disease, and bronchoalveolar 
lavage neutrophilia, levels of regulatory T  cells, chemokines/
cytokines, or matrix metalloproteases have been proposed as 
early biomarkers of BOS (6–10). More recently, expression 
profiling of lung biopsies pinpointed fibrosis-associated genes 
for the diagnosis or prediction of BOS (11). Yet, these invasive 
lung-centered approaches remain hampered by the accessibility 
to such samples and are therefore limited for routine monitor-
ing of lung transplant recipients (LTRs). In blood, circulating 
fibrocytes and cytokine concentration have been proposed as 
predictors of BOS (12–16). However, these studies used a limited 
number of patients and have yet to be confirmed by follow-up 
studies. Consequently, none of these attempts have demonstrated 
sufficient feasibility and robustness to achieve clinical acceptance 
and potential routine use in the future.
Large-scale gene expression profiling of peripheral blood rep-
resents a promising tool to identify transcriptomic markers asso-
ciated with the natural history of an allograft (17). The technique 
has been successfully tested for monitoring kidney (18), heart 
(19), and liver (20) transplant recipients. For the first time, we 
used this non-invasive approach to identify blood biomarkers of 
BOS in a large set of samples from LTRs. By using an independent 
set of patients, we were able to validate a transcriptomic signature 
that predicts the occurrence of BOS more than 6 months before 
the clinical manifestations.
MaTerials anD MeThODs
Patients
Lung transplant recipients were recruited from September 
2009 to October 2013 within the multicentre Cohort of Lung 
Transplantation (COLT) cohort (NCT00980967). The local ethi-
cal committee (Comité de Protection des Personnes Ouest 1-Tours, 
2009-A00036-51) approved the study, and all participants pro-
vided written informed consent. Inclusion criterion was at least 
3 years of follow-up unless the diagnosis of BOS was made before 
(Figure S1 in Supplementary Material).
The eligible patients (n =  688) were phenotyped by a blind 
adjudication committee as described previously (21, 22), based on 
pulmonary function tests and chest imaging according to ISHLT/
ERS/ATS guidelines (3, 23). Assessed pulmonary tests were per-
formed before the transplantation, the day of the transplantation, 
1 and 6  months after the transplantation and every 6  months 
thereafter up to 3  years posttransplantation. We excluded 265 
patients because of other phenotypes or confounding factors, and 
338 stable patients and 85 BOS patients were identified. Stable 
patients displayed no signs of chronic dysfunction for at least 
3 years after lung transplantation. Stable and BOS patients were 
then further selected to constitute homogenous groups based 
on sample availability, absence of concurrent infection or acute 
rejection within 1  month before or after blood collection, and 
the quality of RNA (RNA integrity number ≥6.5). Eighty-nine 
patients (49 STA and 40 BOS) were included in the identification 
set and 25 in the validation set (13 STA and 12 BOS).
rna isolation
Peripheral blood samples were collected in PAXgene tubes 
(PreAnalytix, Qiagen, Hilden, Germany) and stored at −80°C. 
Total RNA was extracted using the PAXgene blood RNA system 
kit (Qiagen) with an on-column DNase digestion protocol 
according to the manufacturer’s instructions. Quantity and 
quality of total RNA were determined using a 2100 Bioanalyzer 
(Agilent Technologies, Palo Alto, CA, USA), and RNA samples 
with an RNA integrity number above 6.5 were selected for further 
analyses.
gene expression Microarray analysis
Total RNA (100 ng) were labeled using the Two-Color Agilent 
Low Input Quick Amp Labeling Kit and hybridized on SurePrint 
G3 Human Gene Expression v3 8 × 60K Microarrays following 
the manufacturer’s instructions (Agilent Technologies). Data 
extraction of median feature intensity was performed with 
Feature Extraction software v10.7 (Agilent Technologies). To 
remove signal intensity bias between each array, median feature 
intensities were normalized with the lowess (locally weighted 
scatter plot smoothing) method, then spots for which half the 
samples exhibited a signal less than the mean of all median signals 
were removed. Correction between two microarray hybridization 
batches was performed on the 28,867 remaining spots with the 
Combat algorithm (24) available through the R package sva (25). 
These normalized microarray data were deposited in the Gene 
Expression Ominbus database (accession number GSE94557). 
Mean expression levels for the spots targeting the same genes 
were assessed, resulting in 16,128 unique genes. In the BOS PRED 
group, the closest time point from transplantation was selected in 
cases of several samples per patient, so that no patient duplicate 
was included. Genes with low variation (i.e., variance <0.2), 
and thus considered as invariants, were excluded, resulting in 
6,581 analyzed genes. For the identification of differential genes, 
linear modeling with empirical Bayes statistical procedure was 
performed, comparing the STA group and each group of interest, 
using the limma package in R. Genes with p < 5% and fold change 
(FC) >1.5 were considered as differentially expressed. The bio-
logical significance of selected genes was assessed using GOminer 
software. Only gene ontology (GO) categories enriched with a 
false discovery rate (FDR) <10% and with at least five represented 
genes were selected. The cell type source of differential genes was 
FigUre 1 | Experimental design. (a) Collection modalities and sample classification. For bronchiolitis obliterans syndrome (BOS) patients, two classes of samples 
were defined depending on the time between blood collection and BOS diagnosis: a prediction class (PRED) combining blood samples collected at least 6 months 
before BOS diagnosis and a diagnosis class (DIAG) combining blood samples collected at or up to 13 months after BOS diagnosis. For STA patients, samples 
collected 6 and 12 months after LT were used. (B) Strategy for gene expression analysis. In both identification and validation sets, STA samples collected 6 months 
posttransplantation were compared with PRED and DIAG class samples. No patient duplicate was included in these groups. For the STA group, comparison 
between gene expression at 6 and 12 months posttransplantation was performed to exclude irrelevant genes modulated with time.
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evaluated using the web tool Enrichr (26). Relative estimation 
of cell abundances using gene expression data was performed 
through the CIBERSORT software (27), and gene set enrichment 
analysis (GSEA) was performed to highlight relevant biological 
processes using curated gene sets from the Molecular Signatures 
Database (1,000 permutations and FDR threshold of 25%) (28).
Quantitative Pcr (qPcr) for Microarray 
Validation
After reverse transcription with Superscript III (Invitrogen, 
Carlsbad, CA, USA), real-time qPCR was performed on a Taqman 
StepOne plus real-time PCR system (Applied Biosystems, Foster 
City, CA, USA) using commercially available primers: HPRT1 
(Hs99999909_m1), β2M (Hs00984230_m1), ACTB (Hs99999903_
m1), CD19 (Hs99999192_m1), TCL1A (Hs00951350_m1), 
IGLL5 (Hs04330879_u1), POU2AF1 (Hs01573371_m1), and 
B  cell lymphocyte kinase (BLK) (Hs01017452_m1). Samples 
were run in duplicate, and the geometric mean of quantification 
cycle values for HPRT1, β2M, and ACTB was used for normaliza-
tion. Relative expression between a sample and a reference was 
calculated according to the 2−ΔΔCt method.
gene expression Data sets
Gene expression values for the three genes of interest (BLK, 
POU2AF1, and TCL1A) from two public microarray data sets 
were collected from the Gene Expression Ominbus database: 
GSE38267 (29) and GSE28042 (30), corresponding to two stud-
ies analyzing blood gene expression in non-transplanted patients 
with terminal respiratory failure.
statistical analysis
Non-parametric Kruskal–Wallis tests with Dunn’s ad  hoc 
pairwise comparisons, Mann–Whitney tests, ROC curves, 
log-ranked survival analyses, and Fisher’s exact test for cat-
egorical variables were performed using GraphPad Prism v. 6 
(GraphPad Software, La Jolla, CA, USA). Time-to-event analysis 
was performed using Cox proportional analysis between gene 
expression and time to BOS with the R survival package (Coxph 
function, R software v. 3.3.2).
resUlTs
lung Transplant recipients
Lung transplant recipients included in this study were recruited 
from the multicentre COLT cohort, allowing for longitudinal 
follow-up and 6-month interval biocollection from transplanta-
tion. On the basis of this longitudinal follow-up, we retrospec-
tively defined two classes of BOS samples depending on the time 
between blood collection and BOS diagnosis (defined as the time 
point with a decline of ≥20% in FEV1 from baseline; Figure 1A). 
Blood samples collected at least 6 months before BOS diagnosis 
were included in the prediction class (PRED), and blood samples 
collected at the time or after BOS diagnosis (up to 13 months after 
initial diagnosis) were included in the diagnosis class (DIAG). For 
the group of patients with stable graft function (STA), blood was 
collected 6 and 12 months after transplantation, and a compari-
son of these two time points was performed to exclude irrelevant 
genes possibly altered during this interval after transplantation 
(Figure 1B). No patient duplicate was included within any classes.
TaBle 1 | Patient characteristics.
identification set Validation set
BOs (N = 40) BOs (N = 12)
sTa  
(N = 49)
Diag  
(N = 26)
PreD 
(N = 32)
sTa  
(N = 13)
Diag  
(N = 8)
PreD 
(N = 11)
Mean age at Tx (range) 40.2 (16–62) 40.6 (15–65) 43.3 (15–65) ns 38.8 (23–62) 50.8 (29–63) 49.5 (27–63) ns
Sex ns ns
M (%) 25 (51) 14 (53.8) 17 (53.1) 7 (53.8) 6 (75) 8 (72.7)
F (%) 24 (49) 12 (46.2) 15 (46.9) 6 (46.2) 2 (25) 3 (27.3)
BMI 20 20.5 21.2 ns 18.7 22.9 21.2 ns
Pathology leading to Tx ns ns
Emphysema/COPD, n (%) 11 (22.4) 8 (30.8) 9 (28.2) 3 (23) 3 (37.5) 5 (45.4)
CF, n (%) 29 (59.2) 9 (30.6) 10 (31.3) 9 (69.2) 2 (25) 4 (36.4)
PAH, n (%) 3 (6.1) 2 (7.7) 2 (6.3) – – –
IPF, n (%) 1 (2) 2 (7.7) 4 (12.5) 1 (7.8) 2 (25) 1 (9.1)
Other, n (%) 5 (10.2) 5 (19.2) 7 (21.9) – 1 (12.5) 1 (9.1)
Type of Tx ns ns
Double lung, n (%) 41 (82.5) 19 (73.1) 24 (75) 11 (84.6) 7 (87.5) 10 (90.9)
Single lung, n (%) 5 (12.5) 6 (23.1) 7 (21.9) 2 (15.4) – –
Heart lung, n (%) 2 (2.5) 1 (3.8) – – 1 (12.5) 1 (9.1)
Lobar, n (%) 1 (2.5) – 1 (3.1) – – –
Induction ns ns
Basiliximab, n (%) 17 (34.7) 5 (19.2) 9 (28.1) 3 (23.1) 1 (12.5) 2 (18.2)
Thymoglobulin, n (%) 17 (34.7) 12 (46.2) 16 (50) 7 (53.8) 1 (12.5) 2 (18.2)
None, n (%) 15 (30.6) 9 (34.6) 7 (21.9) 3 (23.1) 6 (75) 7 (63.6)
Immunosuppressives
Steroids, n (%) 49 (100) 26 (100) 32 (100) 13 (100) 8 (100) 11 (100)
Tacrolimus, n (%) 38 (79.6) 18 (69.2) 23 (71.9) 11 (84.6) 3 (37.5) 6 (54.5)
Cyclosporin, n (%) 11 (22.4) 8 (30.8) 9 (28.1) 2 (15.4) 5 (62.5) 5 (45.4)
MMF/MPA, n (%) 47 (95.9) 26 (100) 29 (90.1) 13 (100) 7 (87.5) 10 (90.1)
Azithromycin 11 (22.4) 20 (76.9)† 12 (37.5) p < 0.0001 6 (46.2) 7 (87.5) 6 (54.5)
Acute cellular rejections ns ns
Ever A1 grade, n (%) 12 (24.5) 7 (26.9) 2 (6.25) 4 (30.7) 5 (62.5) 2 (18.2)
Ever ≥A2 grade, n (%) 4 (8.2) 4 (15.4) 2 (6.25) 1 (7.7) 1 (12.5) 1 (9.1)
Infectionsa ns
Bacteria, n (%) 39 (79.6) 23 (88.5) 28 (87.5) 11 (84.6) 6 (75) 8 (72.7)
Fungi, n (%) 28 (57.2) 21 (80.8) 21 (65.6) 6 (46.2) 4 (50) 7 (63.6)
Virus, n (%) 19 (38.8) 16 (61.5) 14 (43.8) 3 (23) 4 (50) 3 (27.3)
Collection time post-Tx 
(days ± SD)b
6 mo: 196 ± 31 642 ± 254# 210 ± 70## p < 0.0001 6 mo: 185 ± 12 738 ± 86# 311 ± 39## p < 0.0001
12 mo: 375 ± 28 12 mo: 364 ± 9
FEV1 (% predicted) at collectionb 6 mo: 74.5 ± 19.5 50.7 ± 15.5† 72.5 ± 19.9 p < 0.0001 6 mo: 74.7 ± 17.1 57.7 ± 18.9†† 83.4 ± 14.6 0.032
12 mo: 80.6 ± 19.2 12 mo: 81.5 ± 18.4
Smoking status ns ns
Non smoker 30 12 17 9 3 5
Weaned 19 14 13 4 5 6
Active smoker 0 0 2 0 0 0
Clinical parameters of the patients included in the identification and validation sets. The p values were calculated with the Fisher’s exact test for categorical variables and Kruskal–
Wallis test with Dunn’s ad hoc pairwise comparisons for continuous variables.
aNumber of patients with at least one event of infection during the follow-up.
bAt 6 months and 12 months posttransplantation.
#p < 0.05 in DIAG vs. STA 6 mo and PRED.
##p < 0.05 in PRED vs. STA 12 mo.
†p < 0.0001 in DIAG vs. PRED and vs. STA.
††p < 005 in DIAG vs. STA 12 mo.
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Clinical parameters of patients in the identification and valida-
tion sets are presented in Table 1. LTR groups were homogene-
ous regarding age, sex, BMI, type of transplantation, induction 
treatment, smoking status, and infection and rejection events. A 
significant difference in azithromycin exposure was observed in 
the identification set between the DIAG and STA and PRED (76.9 
vs. 22.4 and 37.5%, p < 0.0001). Predicted FEV1 was significantly 
lower in the DIAG in both cohorts (p <  0.05). Time of blood 
collection differed between the DIAG and PRED (p < 0.001).
identification of gene signatures 
associated With BOs
Gene expression profiling evidenced a total of 50 transcripts dif-
ferentially expressed between STA and the 2 DIAG and PRED 
FigUre 2 | Differentially expressed genes. (a) Venn diagram of differentially expressed genes. Numbers of genes differentially expressed comparing STA vs. PRED, 
STA vs. DIAG, and STA at 6 and 12 months posttransplantation are indicated. (B) Principal component analysis and expression heat map (yellow and blue indicate 
high and low expression, respectively, and red and green indicate bronchiolitis obliterans syndrome and STA, respectively).
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BOS groups, excluding differential transcripts between STA at the 
2 time points (Figure  2; Table S1 in Supplementary Material). 
We identified 33 transcripts differentially expressed between STA 
and DIAG. While no GO term was significantly enriched, GSEA 
analysis highlighted 14 enriched gene sets (FDR  <  25% and 
nominal enrichment <−2; Table S2 in Supplementary Material) 
among which 3 were related to B cell biology (31, 32) and one to 
upregulated genes in lung tissue of smokers with chronic obstruc-
tive pulmonary disease (COPD) (33).
Twenty-nine transcripts were differentially expressed between 
STA and PRED. According to the GO analysis, five genes 
participated to the enrichment of the immune system process 
(GO:0002376, FDR = 0.064): CD19 (log2FCPRED/STA = −0.60), the 
major histocompatibility complex class II DQα1 (HLA-DQA1, 
log2FCPRED/STA  =  −0.67) and DQα2 (HLA-DQA2, log2FCPRED/
STA  =  −0.66), POU class 2 associating factor 1 (POU2AF1, 
log2FCPRED/STA = −0.74), and Spi-B transcription factor (SPIB, 
log2FCBOS/STA = −0.6). Analysis using the Enrichr tool stressed the 
enrichment of genes related to CD19+ B  cells including CD19, 
HLA-DQA1, POU2AF1, B lymphoid tyrosine kinase (BLK, 
log2FCPRED/STA  =  −0.62), and T-cell leukemia/lymphoma 1A 
(TCL1A, log2FCPRED/STA = −0.80). Based on unsupervised hier-
archical clustering of expressed genes, these genes clustered with 
known B cell-related genes such as MS4A1 (membrane-spanning 
4-domains, subfamily A, member 14 also called CD20 molecule), 
BANK1 (B cell scaffold protein with ankyrin repeats 1), and CD40, 
reinforcing the potential association of B cell-related genes with 
prediction of BOS. Estimation of memory and plasma B  cells 
relative abundances with gene expression using CIBERSORT did 
not highlighted significant alteration, while naive CD4+ T cells 
abundance was decreased in PRED compared to STA (Figure S2 
in Supplementary Material). It is noteworthy that 14 transcripts, 
including TCL1A, immunoglobulin lambda-like polypeptide 5 
gene (IGLL5), and various immunoglobulin lambda and kappa 
light chain variable regions, were associated with both the DIAG 
and the PRED.
While these results highlight genes differentially expressed 
between STA and each of the two BOS groups, BOS is a time-
dependent phenomenon after lung transplantation. Thus, we 
reanalyzed differential genes from the STA and PRED comparison 
using a time-dependent analysis, the Cox proportional hazards 
test. According to the univariate analysis, all 29 differentially 
expressed genes displayed a significant association with BOS 
occurrence with time (p value of Wald test <0.05; Table S1 in 
Supplementary Material).
Validation of POU2AF1, TCL1A, and BLK 
as Predictive Biomarkers of BOs
Among the differentially expressed genes between STA and 
PRED, five were selected on the basis of their p values, FC mag-
nitude, and expression level in microarrays. These five genes were 
measured by qPCR in an independent set of 25 patients (13 STA 
and 12 BOS), with 11 and 8 samples in the PRED and DIAG, 
respectively (Table  2). Downregulation of 3 genes, POU2AF1 
(p =  0.0065), TCL1A (p =  0.0257), and BLK (p =  0.0221) in 
the PRED was validated by qPCR (Figure  3A). By contrast, 
the downregulation of CD19 and IGLL5 were not confirmed. 
Expression of POU2AF1, TCL1A, and BLK was constant in the 
STA between 6 and 12  months posttransplantation (Figure S3 
in Supplementary Material) but was not significantly down-
regulated at the time of transplantation between STA and PRED 
(n = 6 and 9, respectively; Figure S4 in Supplementary Material). 
For diagnostic purposes, we confirmed the downregulation of 
TCL1A (p = 0.0265; Figure 3B).
Because POU2AF1, TCL1A, and BLK were differentially 
expressed in the PRED, that is, more than 6  months before 
the clinical diagnosis of BOS, we evaluated the predictive 
performance of these three markers using ROC curve analysis. 
POU2AF1 (AUC  =  0.832, 95% CI  =  0.638–1.026), TCL1A 
(AUC = 0.773, 95% CI = 0.553–0.993), and BLK (AUC = 0.780, 
95% CI =  0.569–0.991) discriminated well between STA and 
BOS patients (Figure 4A). Global performances of the predic-
tion presented in Figure 4 show an accuracy higher than 80% 
for the three markers. Due to the high level of correlation 
between the three genes, performance of the prediction was not 
improved by their combination (Figure S5 in Supplementary 
Material).
FigUre 3 | Independent validation. Microarray gene expression data (bar histograms) were validated by quantitative PCR in an independent set of patients (dot 
histograms) comparing STA and PRED (a) and STA and DIAG (B). Mann–Whitney p values are indicated.
TaBle 2 | Microarray-identified genes selected for quantitative PCR (qPCR) validation.
comparison symbol gene name log2Fc (BOs/sTa) Fold change (Fc) [bronchiolitis 
obliterans syndrome (BOs)/sTa]
p Value Wald test
STA vs. PRED CD19 CD19 molecule −0.60 0.66 0.003 0.006
BLK B lymphoid tyrosine kinase −0.62 0.65 0.000 0.001
POU2AF1 POU class 2 associating factor 1 −0.74 0.60 0.001 0.003
TCL1A T-cell leukemia/lymphoma 1A −0.80 0.57 0.003 0.003
IGLL5 Immunoglobulin lambda-like polypeptide 5 −1.18 0.44 0.000 0.001
STA vs. DIAG IGLL5 Immunoglobulin lambda-like polypeptide 5 −0.82 0.57 0.016
TCL1A T-cell leukemia/lymphoma 1A −0.79 0.58 0.006
Five genes were selected for qPCR validation based on their p values and FC magnitude. Gene name, function, p values, and FC values are presented.
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In the survival analysis, these three genes were highly associ-
ated with BOS occurrence with time in the discovery set (BLK, 
p =  0.0013; POU2AF1, p =  0.0028; and TCL1A, p =  0.0031; 
Table S1 in Supplementary Material). The association between 
BOS-free survival and POU2AF1, TCL1A, and BLK was assessed 
through Kaplan–Meier analyses. As shown in Figure 4C, expres-
sion levels of POU2AF1, TCL1A, and BLK under 0.45, 0.34, and 
0.505, respectively (corresponding to best expression thresholds 
according to ROC curves) were associated with significant reduc-
tion of BOS-free survival after lung transplantation (p < 0.01). 
In this validation cohort, 3 of 8 recipients developing BOS had 
donor-specific antibody (DSA) at blood collection vs. none of the 
13 STA (Fisher p = 0.031). Using univariate logistic analysis, DSA 
was not significantly associated with BOS.
POU2AF1, TCL1A, and BLK are 
Downregulated in Blood of Patients with 
end-stage chronic respiratory Diseases
Given the relationship between POU2AF1, TCL1A, and BLK 
expression and the development of BOS, we investigated the 
expression of these three genes in public data sets from blood 
FigUre 4 | Performance of POU2AF1, TCL1A, and B cell lymphocyte kinase (BLK) in prediction of bronchiolitis obliterans syndrome (BOS). (a) ROC curves for 
POU2AF1, TCL1A, and BLK for the prediction of BOS are displayed. (B) Discriminative characteristics of the three genes or the sum of expression of the three 
genes. (c) Kaplan–Meier analysis of BOS-free survival categorized by best expression thresholds of discrimination in ROC curves. Log-ranked p values are 
indicated.
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of patients with other causes of respiratory failure (29, 30). The 
three genes were downregulated in the blood of non-transplanted 
patients with end-stage chronic respiratory diseases (cystic fibro-
sis, idiopathic pulmonary fibrosis, or pulmonary hypertension) 
compared to healthy volunteers (Figure 5).
DiscUssiOn
Bronchiolitis obliterans syndrome is a major limitation of 
long-term survival after lung transplantation. Several previous 
attempts to identify early predictors of BOS remain limited by 
the absence of validation studies (6, 8–10, 12–14). Furthermore, 
they generally relied on invasive procedures incompatible with a 
routine clinical monitoring. We opted for a non-invasive large-
scale molecular profiling approach to identify predictors of BOS 
in whole blood from 89 LTRs. A three-gene molecular signature 
differentiating BOS and STA was validated in an independent 
set of 25 patients. To the best of our knowledge, this is the first 
published study combining two independent cohorts for the 
identification and validation of predictors of BOS.
We showed that 29 and 33 transcripts were differentially 
expressed between STA and DIAG and STA and PRED. Twelve 
transcripts were common between both comparisons. This 
suggests a progression of the molecular profile during the devel-
opment of the disease. Comparison of blood collected 6 and 
12 months after transplantation for the STA group ruled out an 
early time-dependent alteration of gene expression. POU2AF1, 
TCL1A, and BLK were associated with the occurrence of BOS 
with time in a survival analysis and were validated as predictors 
of BOS more than 6 months before its diagnosis. The validation 
cohort used in our study revealed the strength of these biomark-
ers for BOS prediction. They displayed similar performances to 
predict BOS according to their correlation of expression, with 
AUC values reaching 0.83, 0.77, and 0.78, respectively, and 
exceeding the performance of biomarkers already published 
(14, 34, 35).
Recent literature highlights the correlation between de novo 
DSAs with the occurrence of chronic dysfunction (36–40). While 
in our validation cohort DSA was not significantly associated with 
BOS, an independent study is required to decipher whether these 
genes are associated with de novo DSA and BOS appearance and 
which parameter is the most predictive. Furthermore, our inves-
tigation focused on the BOS subtype, and further work will have 
to be conducted to identify predictors of the restrictive syndrome. 
FigUre 5 | B cell lymphocyte kinase (BLK), POU2AF1, and TCL1A 
expression is downregulated by terminal respiratory failure. Expression of 
BLK, POU2AF1, and TCL1A in blood from non-transplanted patients with 
end-stage chronic respiratory diseases, displaying either cystic fibrosis (CF), 
pulmonary hypertension (PAH) (a), or idiopathic pulmonary fibrosis (IPF)  
(B) compared to healthy volunteers (HVs) (29, 30). The p values from 
Kruskal–Wallis tests with Dunn’s ad hoc pairwise comparisons or Mann–
Whitney tests are indicated.
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Besides, stringent patient selection criteria were applied for a 
clear discrimination between groups, and all selected patients 
were not included in the analysis because of feasibility matters. 
This reduction in patient number may limit the generalizability 
of our results, whereas enough power was reached to highlight 
significantly statistical differences for the three genes. Although 
our predictions were confirmed on an independent set of patients, 
they will have to be validated on an external cohort as well.
Our primary objective was to identify a molecular biomarker 
for clinical monitoring in whole blood, which limits the interpre-
tation of mechanistic investigations. Nevertheless, B cell signa-
tures and the presence of B cells with suppressive properties are 
evidenced in other situations of transplantation and particularly 
in tolerance in kidney transplantation (41–43) and/or associated 
with long-term graft survival (44, 45). In a longitudinal study in 
lung transplantation, BOS appearance is associated with a lower 
level of CD24hiCD38hiIgDhiIgMhi transitional B cells with a regula-
tory phenotype 18 months after lung transplantation compared to 
STA (46). We also observed that 12 and 13 transcripts related to 
immunoglobulins are downexpressed in BOS (PRED and DIAG, 
respectively) compared to STA, while gene expression of BAFF 
(B cell activating factor coded by TNFSF13B) and BAFF-R (BAFF 
receptor coded by TNFRSF13C), required for B cell survival and 
maturation, were not different between the three situations (data 
not shown). These data suggest a dysregulation of B cells in the 
BOS situation.
In addition, several genes merit further exploration to better 
understand the underlying mechanism behind BOS. By using 
GO analysis, we evidenced differentially expressed genes between 
STA and PRED associated with immune system process, such 
as CD19, HLA-DQA1, and HLA-DQA2. Interestingly, the gene 
enrichment and unsupervised hierarchical clustering analyses 
reinforce this association of the B cell cluster with the develop-
ment of BOS. POU2AF1 is a B  cell transcriptional coactivator 
involved in B cell development and function (47). Yet, POU2AF1 
is expressed in T cells as well, and recent evidence revealed its 
role in Th1–Th2 polarization (48) and in the mounting of T-cell-
dependent B  cell responses (49). BLK is a member of the Src 
family of tyrosine kinases and encodes a non-receptor protein 
tyrosine kinase involved in the regulation of B  cell receptor 
signaling (50). We found a downregulation of TCL1A in the 
BOS before disease onset. TCL1A is notably expressed by B and 
T lymphocytes, where it promotes cell proliferation and survival 
(51). Interestingly, in renal transplantation, TCL1A is down-
regulated at the time of acute allograft rejection (52), whereas 
it is overexpressed in operationally tolerant patients, an ideal 
situation where recipients are off of immunosuppression with a 
functioning allograft (53). The exact contribution of these genes 
in the development of BOS remains to be investigated. Some 
polymorphisms have been described for BLK, POU2AF1, and 
TCL1A. BLK polymorphism is a risk factor for developing auto-
immune diseases (54, 55). Genetic variations leading to reduced 
BLK expression are associated with several autoimmune diseases 
via lowering the threshold for B cell activation (54). A TCL1A 
single-nucleotide polymorphism is associated with downstream 
expression of cytokines and chemokines and the nuclear factor-
κB transcriptional activity resulting in the modulation of inflam-
mation and immune response (56). POU2AF1 polymorphism 
is associated with susceptibility to lymphoma (57), and mice 
deficient in POU2AF1 exhibit reduced numbers of mature B cells 
and defective immune responses to antigens (58, 59). The fact that 
none of our patients evidenced clinical symptoms or biological 
associated modifications (such as decrease of total B  cells), in 
addition with the absence of differential expression of these three 
genes at the time of transplantation do not suggest existence of 
such polymorphisms in our study. Intriguingly, however, the 
analysis of gene expression data from two independent studies 
(29, 30) revealed that BLK, TCL1A, and POU2AF1 are downregu-
lated in blood from patients with end-stage chronic respiratory 
diseases. GSEA analysis also highlighted the enrichment of a gene 
set related to COPD in lung from smokers in DIAG compared 
to STA, including the SPIB gene (33). Altogether, these results 
suggest common mechanisms between BOS and other chronic 
respiratory diseases, as previously noted (60), and support the 
need to further decipher the roles of POU2AF1, BLK, and TCL1A 
in the development of lung pathologies.
In conclusion, by using non-invasive whole blood profiling, 
we identified and validated POU2AF1, TCL1A, and BLK as three 
predictive biomarkers of BOS, more than 6 months before diag-
nosis. These genes allow stratification based on the BOS risk and 
could be easily monitored to provide clinicians with new tools to 
improve follow-up and adapt treatment of patient likely to develop 
BOS before clinical manifestations and allograft damage arise.
9Danger et al. Blood Gene Expression Predicts BOS
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1841
cOhOrT OF lUng TransPlanTaTiOn
Cohort of Lung Transplantation, COLT (associating surgeons, 
anesthetists-intensivists, physicians, research staff). Bordeaux: J. 
Jougon, J.-F. Velly, H. Rozé, E. Blanchard, C. Dromer. Bruxelles: 
M. Antoine, M. Cappello, R. Souilamas, M. Ruiz, Y. Sokolow, F. 
Vanden Eynden, G. Van Nooten, L. Barvais, J. Berré, S. Brimioulle, 
D. De Backer, J. Créteur, E. Engelman, I. Huybrechts, B. Ickx, T. J. 
C. Preiser, T. Tuna, L. Van Obberghe, N. Vancutsem, J.-L. Vincent, 
P. De Vuyst, I. Etienne, F. Féry, F. Jacobs, C. Knoop, J. L. Vachiéry, 
P. Van den Borne, I. Wellemans, G. Amand, L. Collignon, M. 
Giroux. Grenoble: E. Arnaud-Crozat, V. Bach, P.-Y. Brichon, P. 
Chaffanjon, O. Chavanon, A. de Lambert, J. P. Fleury, S. Guigard, 
K. Hireche, A. Pirvu, P. Porcu, R. Hacini, P. Albaladejo, C. Allègre, 
A. Bataillard, D. Bedague, E. Briot, M. Casez-Brasseur, D. Colas, G. 
Dessertaine, M. Durand, G. Francony, A. Hebrard, M. R. Marino, 
B. Oummahan, D. Protar, D. Rehm, S. Robin, M. Rossi-Blancher, 
P. Bedouch, A. Boignard, H. Bouvaist, A. Briault, B. Camara, S. 
Chanoine, M. Dubuc, S. Lantuéjoul, S. Quétant, J. Maurizi, P. 
Pavèse, C. Pison, C. Saint-Raymond, N. Wion, C. Chérion. Lyon: 
R. Grima, O. Jegaden, J.-M. Maury, F. Tronc, C. Flamens, S. Paulus, 
J. F. Mornex, F. Philit, A. Senechal, J.-C. Glérant, S. Turquier, D. 
Gamondes, L. Chalabresse, F. Thivolet-Bejui, C. Barnel, C. Dubois, 
A. Tiberghien. Paris, Hôpital Européen Georges Pompidou: F. 
Le Pimpec-Barthes, A. Bel, P. Mordant, P. Achouh, V. Boussaud, 
R. Guillemain, D. Méléard, M. O. Bricourt, B. Cholley, V. Pezella. 
Marseille: M. Adda, M. Badier, F. Bregeon, B. Coltey, X. B. D’Journo, 
S. Dizier, C. Doddoli, N. Dufeu, H. Dutau, J. M. Forel, J. Y. Gaubert, 
C. Gomez, M. Leone, A. Nieves, B. Orsini, L. Papazian L. C. Picard, 
M. Reynaud-Gaubert, A. Roch, J. M. Rolain, E. Sampol, V. Secq, 
P. Thomas, D. Trousse, M. Yahyaoui. Nantes: O. Baron, P. Lacoste, 
C. Perigaud, J. C. Roussel, I. Danner, A Haloun, A. Magnan, A. 
Tissot, T. Lepoivre, M. Treilhaud, K. Botturi-Cavaillès, S. Brouard, 
R. Danger, J. Loy, M. Morisset, M. Pain, S. Pares, D. Reboulleau, 
P. J. Royer, E. Durand, A. Foureau. Le Plessis Robinson, Hôpital 
Marie Lannelongue: Ph. Dartevelle, D. Fabre, E. Fadel, O. 
Mercier, S. Mussot, F. Stephan, P. Viard, J. Cerrina, P. Dorfmuller, 
S. Feuillet, M. Ghigna, Ph. Hervén, F. Le Roy Ladurie, J. Le Pavec, 
V. Thomas de Montpreville, L. Lamrani. Paris, Hôpital Bichat: Y. 
Castier, P. Cerceau, F. Francis, G. Lesèche, N. Allou, P. Augustin, S. 
Boudinet, M. Desmard, G. Dufour, P. Montravers, O. Brugière, G. 
Dauriat, G. Jébrak, H. Mal, A. Marceau, A.-C. Métivier, G. Thabut, 
B. Ait Ilalne. Strasbourg: P. Falcoz, G. Massard, N. Santelmo, G. 
Ajob, O. Collange, O. Helms, J. Hentz, A. Roche, B. Bakouboula, 
T. Degot, A. Dory, S. Hirschi, S. Ohlmann-Caillard, L. Kessler, R. 
Kessler, A. Schuller, K. Bennedif, S. Vargas. Suresnes, Hôpital 
Foch: P. Bonnette, A. Chapelier, P. Puyo, E. Sage, J. Bresson, V. 
Caille, C. Cerf, J. Devaquet, V. Dumans-Nizard, M. L. Felten, M. 
Fischler, A. G. Si Larbi, M. Leguen, L. Ley, N. Liu, G. Trebbia, S. 
De Miranda, B. Douvry, F. Gonin, D. Grenet, A. M. Hamid, H. 
Neveu, F. Parquin, C. Picard, A. Roux, M. Stern, F. Bouillioud, P. 
Cahen, M. Colombat, C. Dautricourt, M. Delahousse, B. D’Urso, 
J. Gravisse, A. Guth, S. Hillaire, P. Honderlick, M. Lequintrec, E. 
Longchampt, F. Mellot, A. Scherrer, L. Temagoult, L. Tricot, M. 
Vasse, C. Veyrie, L. Zemoura. Toulouse: J. Berjaud, L. Brouchet, 
M. Dahan, F. Le Balle, O. Mathe, H. Benahoua, A. Didier, A. L. 
Goin, M. Murris, L. Crognier, O. Fourcade.
Swiss Transplant Cohort Study, STCS Genève-Lausanne. 
T. Krueger, H. B. Ris, M. Gonzalez, J.-D. Aubert, L. P. Nicod, 
B. J. Marsland, T. C. Berutto, T. Rochat, P. Soccal, Ph. Jolliet, A. 
Koutsokera, C. Marcucci, O. Manuel, E. Bernasconi, M. Chollet, 
F. Gronchi, C. Courbon, Zurich S. Hillinger, I. Inci, P. Kestenholz, 
W. Weder, R. Schuepbach, M. Zalunardo, C. Benden, U. Buergi, 
L. C. Huber, B. Isenring, M. M. Schuurmans, A. Gaspert, D. 
Holzmann, N. Müller, C. Schmid, B. Vrugt, T. Rechsteiner.
SME and Platforms. Biomax, Germany: A. Fritz, D. 
Maier. Finovatis, Lyon, France: K. Desplanche, D. Koubi. 
GATC, Germany: F. Ernst, T. Paprotka, M. Schmitt, B. Wahl. 
Novasdicovery, Lyon, France: J.-P. Boissel, G. Olivera-Botello. 
Prométhée Proteomics Platform, Grenoble, France: C. Trocmé, 
B. Toussaint, S. Bourgoin-Voillard, M. Séve. INSERM U823, 
Université Joseph Fourier, Grenoble, France, M. Benmerad, 
V. Siroux, R. Slama. European Institute for Systems Biology 
& Medicine, Lyon, France: C. Auffray, D. Charron, J. Pellet, 
C. Pison.
eThics sTaTeMenT
Lung transplant recipients were recruited from September 2009 
to October 2013 within the multicentre COLT cohort (Cohort of 
Lung Transplantation; NCT00980967). The local ethical commit-
tee (Comité de Protection des Personnes Ouest 1-Tours, 2009-
A00036-51) approved the study, and all participants provided 
written informed consent.
aUThOr cOnTriBUTiOns
Conceived and designed the experiments/analyses: RD, PJR, SB, 
AM. Performed the experiments: RD, PJR, ED, JL. Analyzed the 
data: RD, PJR. Contributed samples/materials: DR, AT, PL, AR, 
MRG, CG, RK, SM, CD, OB, JFM, RG, MD, CK, KB, AF, CP, AK, 
LPN. Wrote the paper: RD, PJR, SB, AM. All authors approved the 
final version of the article.
acKnOWleDgMenTs
We are most grateful to the GenoBiRD Core Facility for its techni-
cal support and to the biological resource center for biobanking 
CHU Nantes, Hôtel Dieu, Centre de ressources biologiques 
(CRB), Nantes, F-44093, France (BRIF: BB-0033-00040).
FUnDing
This research program was supported by Vaincre la Mucoviscidose, 
Association Gregory Lemarchal, Agence de Biomédecine, 
INSERM, Région Pays de La Loire, Institut de Recherche en 
Santé Respiratoire des Pays de la Loire, Fonds de Recherche en 
Santé Respiratoire, Fondation du Souffle, and Fondation pour 
la Recherche Médicale. This work was realized in the context of 
the IHU-Cesti project, the DHU Oncogreffe and the LabEX IGO 
thanks to French government financial support managed by the 
National Research Agency via the “Investment into the Future” 
program (ANR-10-IBHU-005 and ANR-11- LABX-0016-01). 
10
Danger et al. Blood Gene Expression Predicts BOS
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1841
The IHU-Cesti project is also supported by Nantes Métropole and 
Région Pays de la Loire. The research leading to these results has 
also received funding from the European Commission’s Seventh 
Framework Program FP7 VISICORT under grant agreement n 
602470.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://www.frontiersin.org/articles/10.3389/fimmu.2017.01841/
full#supplementary-material.
reFerences
1. Royer PJ, Olivera-Botello G, Koutsokera A, Aubert JD, Bernasconi E, Tissot A, 
et al. Chronic lung allograft dysfunction: a systematic review of mechanisms. 
Transplantation (2016) 100(9):1803–14. doi:10.1097/TP.0000000000001215 
2. Sato M. Chronic lung allograft dysfunction after lung transplantation: the 
moving target. Gen Thorac Cardiovasc Surg (2013) 61(2):67–78. doi:10.1007/
s11748-012-0167-3 
3. Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, et al. 
An international ISHLT/ATS/ERS clinical practice guideline: diagnosis 
and management of bronchiolitis obliterans syndrome. Eur Respir J (2014) 
44(6):1479–503. doi:10.1183/09031936.00107514 
4. Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, et al. 
Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft 
dysfunction. J Heart Lung Transplant (2011) 30(7):735–42. doi:10.1016/j.
healun.2011.01.712 
5. Sato M, Keshavjee S. Bronchiolitis obliterans syndrome: alloimmune- 
dependent and -independent injury with aberrant tissue remodeling. Semin 
Thorac Cardiovasc Surg (2008) 20(2):173–82. doi:10.1053/j.semtcvs.2008. 
05.002 
6. Devouassoux G, Drouet C, Pin I, Brambilla C, Brambilla E, Colle PE, et al. 
Alveolar neutrophilia is a predictor for the bronchiolitis obliterans syndrome, 
and increases with degree of severity. Transpl Immunol (2002) 10(4):303–10. 
doi:10.1016/S0966-3274(02)00074-6 
7. Neurohr C, Huppmann P, Samweber B, Leuschner S, Zimmermann G, 
Leuchte H, et al. Prognostic value of bronchoalveolar lavage neutrophilia in 
stable lung transplant recipients. J Heart Lung Transplant (2009) 28(5):468–74. 
doi:10.1016/j.healun.2009.01.014 
8. Reynaud-Gaubert M, Marin V, Thirion X, Farnarier C, Thomas P, Badier M, 
et al. Upregulation of chemokines in bronchoalveolar lavage fluid as a predic-
tive marker of post-transplant airway obliteration. J Heart Lung Transplant 
(2002) 21(7):721–30. doi:10.1016/S1053-2498(02)00392-3 
9. Hübner RH, Meffert S, Mundt U, Böttcher H, Freitag S, El Mokhtari NE, et al. 
Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung 
transplantation. Eur Respir J (2005) 25(3):494–501. doi:10.1183/09031936.0
5.00091804 
10. Bhorade SM, Chen H, Molinero L, Liao C, Garrity ER, Vigneswaran WT, 
et al. Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage 
from lung transplant recipients correlates with development of bronchiolitis 
obliterans syndrome. Transplantation (2010) 90(5):540–6. doi:10.1097/
TP.0b013e3181e8dabe 
11. Jonigk D, Izykowski N, Rische J, Braubach P, Kühnel M, Warnecke G, et al. 
Molecular profiling in lung biopsies of human pulmonary allografts to 
predict chronic lung allograft dysfunction. Am J Pathol (2015) 185:3178–88. 
doi:10.1016/j.ajpath.2015.08.016 
12. Shah RJ, Bellamy SL, Lee JC, Cantu E, Diamond JM, Mangalmurti N, et al. 
Early plasma soluble receptor for advanced glycation end-product levels are 
associated with bronchiolitis obliterans syndrome. Am J Transplant (2013) 
13(3):754–9. doi:10.1111/ajt.12062 
13. Salama M, Jaksch P, Andrukhova O, Taghavi S, Klepetko W, Aharinejad S. 
Endothelin-1 is a useful biomarker for early detection of bronchiolitis 
obliterans in lung transplant recipients. J Thorac Cardiovasc Surg (2010) 
140(6):1422–7. doi:10.1016/j.jtcvs.2010.08.046 
14. Paantjens AWM, Kwakkel-van Erp JM, Van Ginkel WGJ, Van Kessel DA, 
Van Den Bosch JMM, Van De Graaf EA, et al. Serum thymus and activation 
regulated chemokine levels post-lung transplantation as a predictor for the 
bronchiolitis obliterans syndrome. Clin Exp Immunol (2008) 154(2):202–8. 
doi:10.1111/j.1365-2249.2008.03764.x 
15. LaPar DJ, Burdick MD, Emaminia A, Harris DA, Strieter BA, Liu L, et  al. 
Circulating fibrocytes correlate with bronchiolitis obliterans syndrome 
development after lung transplantation: a novel clinical biomarker. Ann 
Thorac Surg (2011) 92(2):470–7. doi:10.1016/j.athoracsur.2011.04.065 
16. Weigt SS, Wang X, Palchevskiy V, Gregson AL, Patel N, DerHovanessian A, 
et al. Gene expression profiling of bronchoalveolar lavage cells preceding a 
clinical diagnosis of chronic lung allograft dysfunction. PLoS One (2017) 
12(1):e0169894. doi:10.1371/journal.pone.0169894 
17. Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft 
rejection and outcome using gene expression patterns. Transplantation  
(2008) 86(2):192–9. doi:10.1097/TP.0b013e31817eef7b 
18. Brouard S, Mansfield E, Braud C, Li L, Giral M, Hsieh SC, et al. Identification 
of a peripheral blood transcriptional biomarker panel associated with 
operational renal allograft tolerance. Proc Natl Acad Sci U S A (2007) 
104(39):15448–53. doi:10.1073/pnas.0705834104 
19. Chen Y, Zhang H, Xiao X, Jia Y, Wu W, Liu L, et  al. Peripheral blood 
transcriptome sequencing reveals rejection-relevant genes in long-term 
heart transplantation. Int J Cardiol (2013) 168(3):2726–33. doi:10.1016/j.
ijcard.2013.03.095 
20. Kurian SM, Fouraschen SMG, Langfelder P, Horvath S, Shaked A, Salomon DR, 
et al. Genomic profiles and predictors of early allograft dysfunction after human 
liver transplantation. Am J Transplant (2015) 15(6):1605–14. doi:10.1111/ 
ajt.13145 
21. Pain M, Royer PJ, Loy J, Girardeau A, Tissot A, Lacoste P, et al. T cells promote 
bronchial epithelial cell secretion of matrix metalloproteinase-9 via a C-C 
chemokine receptor type 2 pathway: implications for chronic lung allograft 
dysfunction. Am J Transplant (2016) 17(6):1502–14. doi:10.1111/ajt.14166 
22. Koutsokera A, Royer PJ, Antonietti JP, Fritz A, Benden C, Aubert JD, et al. 
Development of a multivariate prediction model for early-onset bronchiolitis 
obliterans syndrome and restrictive allograft syndrome in lung transplanta-
tion. Front Med (2017) 4:109. doi:10.3389/fmed.2017.00109 
23. Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classifica-
tion system for chronic lung allograft dysfunction. J Heart Lung Transplant 
(2014) 33(2):127–33. doi:10.1016/j.healun.2014.01.316 
24. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expres-
sion data using empirical Bayes methods. Biostatistics (2007) 8(1):118–27. 
doi:10.1093/biostatistics/kxj037 
25. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The SVA package for 
removing batch effects and other unwanted variation in high-throughput 
experiments. Bioinformatics (2012) 28(6):882–3. doi:10.1093/bioinformatics/
bts034 
26. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, 
et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 
update. Nucleic Acids Res (2016) 44(W1):W90–7. doi:10.1093/nar/gkw377 
27. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust 
enumeration of cell subsets from tissue expression profiles. Nat Methods 
(2015) 12(5):453–7. doi:10.1038/nmeth.3337 
28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, 
et al. Gene set enrichment analysis: a knowledge-based approach for inter-
preting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 
102(43):15545–50. doi:10.1073/pnas.0506580102 
29. Chesne J, Danger R, Botturi K, Reynaud-Gaubert M, Mussot S, Stern M, 
et  al. Systematic analysis of blood cell transcriptome in end-stage chronic 
respiratory diseases. PLoS One (2014) 9(10):e109291. doi:10.1371/journal.
pone.0109291 
30. Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma SF, Tseng GC, et al. Peripheral 
blood mononuclear cell gene expression profiles predict poor outcome 
in idiopathic pulmonary fibrosis. Sci Transl Med (2013) 5(205):205ra136. 
doi:10.1126/scitranslmed.3005964 
31. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. 
Reverse engineering of regulatory networks in human B  cells. Nat Genet 
(2005) 37(4):382–90. doi:10.1038/ng1532 
11
Danger et al. Blood Gene Expression Predicts BOS
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1841
32. Haddad R, Guardiola P, Izac B, Thibault C, Radich J, Delezoide AL, et  al. 
Molecular characterization of early human T/NK and B-lymphoid progenitor 
cells in umbilical cord blood. Blood (2004) 104(13):3918–26. doi:10.1182/
blood-2004-05-1845 
33. Ning W, Li CJ, Kaminski N, Feghali-Bostwick CA, Alber SM, Di YP, et  al. 
Comprehensive gene expression profiles reveal pathways related to the patho-
genesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A 
(2004) 101(41):14895–900. doi:10.1073/pnas.0401168101 
34. Budding K, van de Graaf EA, Kardol-Hoefnagel T, Kwakkel-van Erp JM, 
Luijk BD, Oudijk E-JD, et  al. Soluble CD59 is a novel biomarker for the 
prediction of obstructive chronic lung allograft dysfunction after lung trans-
plantation. Sci Rep (2016) 6:26274. doi:10.1038/srep26274 
35. Jaksch P, Taghavi S, Klepetko W, Salama M. Pretransplant serum human 
chitinase-like glycoprotein YKL-40 concentrations independently predict 
bronchiolitis obliterans development in lung transplant recipients. J Thorac 
Cardiovasc Surg (2014) 148(1):273–81. doi:10.1016/j.jtcvs.2014.02.059 
36. Roux A, Bendib Le Lan I, Holifanjaniaina S, Thomas KA, Hamid AM, 
Picard C, et al. Antibody-mediated rejection in lung transplantation: clinical 
outcomes and donor-specific antibody characteristics. Am J Transplant (2016) 
16(4):1216–28. doi:10.1111/ajt.13589 
37. Le Pavec J, Suberbielle C, Lamrani L, Feuillet S, Savale L, Dorfmüller P, et al. 
De-novo donor-specific anti-HLA antibodies 30 days after lung transplan-
tation are associated with a worse outcome. J Heart Lung Transplant (2016) 
35(9):1067–77. doi:10.1016/j.healun.2016.05.020 
38. Tikkanen JM, Singer LG, Kim SJ, Li Y, Binnie M, Chaparro C, et al. De novo 
DQ donor-specific antibodies are associated with chronic lung allograft 
dysfunction after lung transplantation. Am J Respir Crit Care Med (2016) 
194(5):596–606. doi:10.1164/rccm.201509-1857OC 
39. Morrell MR, Pilewski JM, Gries CJ, Pipeling MR, Crespo MM, Ensor CR, 
et al. De novo donor-specific HLA antibodies are associated with early and 
high-grade bronchiolitis obliterans syndrome and death after lung trans-
plantation. J Heart Lung Transplant (2014) 33(12):1288–94. doi:10.1016/j.
healun.2014.07.018 
40. Safavi S, Robinson DR, Soresi S, Carby M, Smith JD. De novo donor HLA-
specific antibodies predict development of bronchiolitis obliterans syndrome 
after lung transplantation. J Heart Lung Transplant (2014) 33(12):1273–81. 
doi:10.1016/j.healun.2014.07.012 
41. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, et al. 
Identification of a B cell signature associated with renal transplant tolerance 
in humans. J Clin Invest (2010) 120(6):1836–47. doi:10.1172/JCI39933 
42. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, et  al. 
Development of a cross-platform biomarker signature to detect renal trans-
plant tolerance in humans. J Clin Invest (2010) 120(6):1848–61. doi:10.1172/
JCI39922 
43. Pallier A, Hillion S, Danger R, Giral M, Racape M, Degauque N, et  al. 
Patients with drug-free long-term graft function display increased numbers 
of peripheral B  cells with a memory and inhibitory phenotype. Kidney Int 
(2010) 78(5):503–13. doi:10.1038/ki.2010.162 
44. Heidt S, Hester J, Shankar S, Friend PJ, Wood KJ. B cell repopulation after 
alemtuzumab induction-transient increase in transitional B  cells and long-
term dominance of naive B  cells. Am J Transplant (2012) 12(7):1784–92. 
doi:10.1111/j.1600-6143.2012.04012.x 
45. Shabir S, Girdlestone J, Briggs D, Kaul B, Smith H, Daga S, et al. Transitional 
B lymphocytes are associated with protection from kidney allograft rejection: 
a prospective study. Am J Transplant (2015) 15(5):1384–91. doi:10.1111/
ajt.13122 
46. Brosseau C, Durand M, Durand E, Loy J, Foureau A, Lacoste P, et  al. 
Characterization of a B lymphocyte signature predictive of chronic lung 
allograft dysfunction. Am J Transplant (2017) 17(Suppl 3). doi:10.1111/
ajt.14304
47. Luo Y, Fujii H, Gerster T, Roeder RG. A novel B cell-derived coactivator poten-
tiates the activation of immunoglobulin promoters by octamer-binding tran-
scription factors. Cell (1992) 71(2):231–41. doi:10.1016/0092-8674(92)90352-D 
48. Brunner C, Sindrilaru A, Girkontaite I, Fischer K-D, Sunderkötter C, 
Wirth T. BOB.1/OBF.1 controls the balance of TH1 and TH2 immune 
responses. EMBO J (2007) 26(13):3191–202. doi:10.1038/sj.emboj.7601742 
49. Stauss D, Brunner C, Berberich-Siebelt F, Höpken UE, Lipp M, Müller G. 
The transcriptional coactivator Bob1 promotes the development of fol-
licular T helper cells via Bcl6. EMBO J (2016) 35(8):881–98. doi:10.15252/
embj.201591459 
50. Dymecki SM, Niederhuber JE, Desiderio SV. Specific expression of a tyro-
sine kinase gene, blk, in B lymphoid cells. Science (1990) 247(4940):332–6. 
doi:10.1126/science.2404338 
51. Laine J, Künstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 
is an Akt kinase coactivator. Mol Cell (2000) 6(2):395–407. doi:10.1016/
S1097-2765(00)00039-3 
52. Heidt S, Vergunst M, Anholts JD, Reinders ME, de Fijter JW, Eikmans M, et al. 
B cell markers of operational tolerance can discriminate acute kidney allograft 
rejection from stable graft function. Transplantation (2014) 99(5):1058–64. 
doi:10.1097/00007890-201407151-03002 
53. Danger R, Chesneau M, Paul C, Guerif P, Durand M, Newell KA, et  al. A 
composite score associated with spontaneous operational tolerance in 
kidney transplant recipients. Kidney Int (2017) 91(6):1473–81. doi:10.1016/j.
kint.2016.12.020 
54. Simpfendorfer KR, Armstead BE, Shih A, Li W, Curran M, Manjarrez- 
Orduno N, et  al. Autoimmune disease-associated haplotypes of BLK 
exhibit lowered thresholds for B  cell activation and expansion of Ig class-
switched B  cells. Arthritis Rheumatol (2015) 67(11):2866–76. doi:10.1002/ 
art.39301 
55. Zeng C, Fang C, Weng H, Xu X, Wu T, Li W. B-cell lymphocyte kinase 
polymorphisms rs13277113, rs2736340, and rs4840568 and risk of autoim-
mune diseases: a meta-analysis. Medicine (2017) 96(36):e7855. doi:10.1097/
MD.0000000000007855 
56. Ho MF, Ingle JN, Bongartz T, Kalari KR, Goss PE, Shepherd LE, et  al. 
TCL1A single-nucleotide polymorphisms and estrogen-mediated toll-like 
receptor-MYD88-dependent nuclear factor-kappaB activation: single- 
nucleotide polymorphism- and selective estrogen receptor modulator-depen-
dent modification of inflammation and immune response. Mol Pharmacol 
(2017) 92(2):175–84. doi:10.1124/mol.117.108340 
57. Zhai K, Chang J, Hu J, Wu C, Lin D. Germline variation in the 3’-untranslated 
region of the POU2AF1 gene is associated with susceptibility to lymphoma. 
Mol Carcinog (2017) 56(8):1945–52. doi:10.1002/mc.22652 
58. Nielsen PJ, Georgiev O, Lorenz B, Schaffner W. B lymphocytes are impaired 
in mice lacking the transcriptional co-activator Bob1/OCA-B/OBF1. Eur 
J Immunol (1996) 26(12):3214–8. doi:10.1002/eji.1830261255 
59. Schubart DB, Rolink A, Kosco-Vilbois MH, Botteri F, Matthias P. B-cell-specific 
coactivator OBF-1/OCA-B/Bob1 required for immune response and germinal 
centre formation. Nature (1996) 383(6600):538–42. doi:10.1038/383538a0 
60. Fernandez IE, Heinzelmann K, Verleden S, Eickelberg O. Characteristic 
patterns in the fibrotic lung. Comparing idiopathic pulmonary fibrosis with 
chronic lung allograft dysfunction. Ann Am Thorac Soc (2015) 12(Suppl 1): 
S34–41. doi:10.1513/AnnalsATS.201410-476MG 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Danger, Royer, Reboulleau, Durand, Loy, Tissot, Lacoste, Roux, 
Reynaud-Gaubert, Gomez, Kessler, Mussot, Dromer, Brugière, Mornex, Guillemain, 
Dahan, Knoop, Botturi, Foureau, Pison, Koutsokera, Nicod, Brouard, Magnan and 
The COLT and SysCLAD Consortia. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License (CC BY). The use, distribu-
tion or reproduction in other forums is permitted, provided the original author(s) 
or licensor are credited and that the original publication in this journal is cited, in 
accordance with accepted academic practice. No use, distribution or reproduction is 
permitted which does not comply with these terms.
